{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:26:52Z","timestamp":1792466812534,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T00:00:00Z","timestamp":1561248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Circulating platelet micro\u2010RNAs (miRNAs) may be used to monitor platelet function during dual antiplatelet therapy (DAPT). Aim of the study was to measure plasma levels of specific miRNAs (miRNA\u2010223, \u2010150, \u201021 and \u2010126) after physician\u2010driven cessation of chronic P2Y12 inhibition and to study differences in the expression levels of these miRNAs between the different oral P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Patients with coronary artery disease (CAD) on DAPT maintenance dose (including aspirin 100\u00a0mg OD, plus clopidogrel 75\u00a0mg OD, or prasugrel 10\u00a0mg OD, or ticagrelor 90\u00a0mg BID) were prospectively enrolled before cessation of the P2Y12\u2010inhibitor therapy. MiRNA\u2010223, \u2010150, \u201021 and \u2010126 were determined at baseline (=last day of P2Y12\u2010inhibitor intake) and 10, 30 and 180\u00a0days thereafter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cessation of P2Y12\u2010inhibitor therapy did not significantly change miRNA levels. However, in ticagrelor\u2010treated patients, miRNA levels were significantly increased at baseline (miRNA\u2010223 and \u201021), day 10 (miRNA\u2010223, \u2010150, \u201021, \u2010126) and day 30 (miRNA\u2010223, \u2010150, \u201021, \u2010126) as compared to prasugrel, and at day 10 (miRNA\u2010150 and \u201021) and day 30 (miRNA\u2010150) as compared to clopidogrel (all <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). At day 180, only miRNA\u2010126 levels differed significantly with respect to the P2Y12 inhibitor used (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). After adjustment for confounders, choice of P2Y12\u2010inhibitor was the strongest predictor of miRNA levels (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), while cessation of P2Y12\u2010inhibitor therapy did not significantly impact miRNA levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with CAD, ticagrelor intake is associated with increased levels of platelet miRNAs as compared to clopidogrel and prasugrel. Platelet miRNAs are not useful to monitor platelet function after cessation of P2Y12 inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.13149","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T06:35:12Z","timestamp":1559889312000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Course of platelet miRNAs after cessation of P2Y12 antagonists"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-086X","authenticated-orcid":false,"given":"Bernhard","family":"J\u00e4ger","sequence":"first","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"},{"name":"Medical Faculty Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stojkovic","sequence":"additional","affiliation":[{"name":"Department of Cardiology Medical University of Vienna, University Clinic for Internal Medicine II Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Haller","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Piackova","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijana","family":"Andric","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris G.","family":"Vargas","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-9276","authenticated-orcid":false,"given":"Johann","family":"Wojta","sequence":"additional","affiliation":[{"name":"Department of Cardiology Medical University of Vienna, University Clinic for Internal Medicine II Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"Wilhelminenhospital 3rd Medical Department with Cardiology Vienna Austria"},{"name":"Medical Faculty Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,23]]},"reference":[{"issue":"35","key":"e_1_2_9_2_1","first-page":"2541","article-title":"ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio\u2010Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"2014","author":"Authors TF","year":"2014","journal-title":"Eur Heart J"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvw174"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvt161"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvu039"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.056"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.02.015"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-013-1022-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.300539"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.003"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.890707"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.055"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2014.974527"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02234.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03584.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804549105"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.01.020"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-05-0242"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.66"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.414"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-04-0273"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3968206"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-011-0310-7"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1651"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.13149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/eci.13149","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.13149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T22:08:52Z","timestamp":1694297332000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.13149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/eci.13149"],"URL":"https:\/\/doi.org\/10.1111\/eci.13149","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,23]]},"assertion":[{"value":"2018-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13149"}}